학술논문
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer
Document Type
Article
Author
Source
In Gynecologic Oncology November 2023 178:27-35
Subject
Language
ISSN
0090-8258